Kawasaki disease is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of Kawasaki disease requires individual development of treatment programs, typically including drug therapy, rehabilitation interventions, and regular follow-up multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely schemes according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of Kawasaki disease. The platform serves the China International Medical Service System, a team of authoritative experts at home and abroad in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.